Hanall Biopharma (009420) — Net Asset Quality Index
Hanall Biopharma (009420) has a Net Asset Quality Index of 78.1% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of ₩201.82 Billion minus total liabilities of ₩44.17 Billion yields net assets of ₩157.65 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check 009420 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Hanall Biopharma Net Asset Quality Index Over Time (2011–2024)
This chart shows how Hanall Biopharma's Net Asset Quality Index has evolved across 14 annual periods from 2011 to 2024. As of September 2025, the index stands at 78.1%, representing net assets of ₩157.65 Billion against total assets of ₩201.82 Billion KRW. See 009420 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Hanall Biopharma (2011–2024)
The table below presents the year-by-year Net Asset Quality Index for Hanall Biopharma from 2011 to 2024, covering 14 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Hanall Biopharma (009420) market capitalisation.
| Year | Quality Index | Net Assets (KRW) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 79.1% | ₩168.35 Billion | ₩212.88 Billion | ₩44.53 Billion | ▲ +1.4 pp |
| 2023 | 77.7% | ₩186.22 Billion | ₩239.75 Billion | ₩53.53 Billion | ▼ -1.2 pp |
| 2022 | 78.8% | ₩168.26 Billion | ₩213.45 Billion | ₩45.19 Billion | ▼ -3.5 pp |
| 2021 | 82.4% | ₩163.49 Billion | ₩198.48 Billion | ₩34.99 Billion | ▲ +0.0 pp |
| 2020 | 82.3% | ₩181.27 Billion | ₩220.13 Billion | ₩38.86 Billion | ▲ +9.0 pp |
| 2019 | 73.4% | ₩140.42 Billion | ₩191.38 Billion | ₩50.97 Billion | ▲ +1.3 pp |
| 2018 | 72.0% | ₩116.92 Billion | ₩162.30 Billion | ₩45.39 Billion | ▲ +6.1 pp |
| 2017 | 65.9% | ₩111.20 Billion | ₩168.70 Billion | ₩57.50 Billion | ▼ -17.7 pp |
| 2016 | 83.7% | ₩104.36 Billion | ₩124.73 Billion | ₩20.37 Billion | ▲ +2.4 pp |
| 2015 | 81.3% | ₩95.22 Billion | ₩117.13 Billion | ₩21.91 Billion | ▲ +28.7 pp |
| 2014 | 52.6% | ₩45.81 Billion | ₩87.17 Billion | ₩41.36 Billion | ▼ -8.4 pp |
| 2013 | 60.9% | ₩59.63 Billion | ₩97.85 Billion | ₩38.23 Billion | ▼ -2.4 pp |
| 2012 | 63.3% | ₩78.67 Billion | ₩124.27 Billion | ₩45.60 Billion | ▲ +15.2 pp |
| 2011 | 48.1% | ₩50.70 Billion | ₩105.46 Billion | ₩54.75 Billion | — |